Myth or fact

A statin lowers ApoB as much as it lowers LDL

Short answerNo

By GyroscopeUpdated November 15, 20264 sources

Keep taking your medicine as prescribed. This page explains why ApoB and LDL fall by different amounts. Any change to your treatment is your prescriber’s decision.

No. Across 11 trials of LDL-lowering medicine, LDL fell 42% on average and ApoB fell 33%. A statin thins out the cholesterol faster than it thins out the particles, so your LDL can reach its goal while your ApoB is still over its own. The 2026 US guideline says checking ApoB at that point is reasonable.

Why people believe it

Every LDL particle carries one ApoB, so it seems logical that taking LDL down by some amount would take ApoB down by the same amount. A statin’s success is usually judged by LDL alone, and once LDL hits its goal the conversation tends to stop. If nobody measures ApoB, nobody sees the gap.

What the trials show

The National Lipid Association’s 2024 consensus pooled 11 trials of LDL-lowering medicine, 9 with a statin alone and 2 with a statin plus ezetimibe. On average, LDL fell 42% and ApoB fell 33%.

Start both numbers at 100 and the average result leaves LDL at 58 and ApoB at 67. After a heart attack, where the LDL goal is under 55 and the matched ApoB goal is under 60, the LDL is 3 points from its goal and the ApoB is 7.

For one person the split can be much bigger than the average. Take someone with a stent, on a statin, with an LDL of 52 and an ApoB of 88. The LDL is under its goal of 55. The ApoB is 28 points over 60. That’s the case the guideline’s ApoB recommendation was written for.

Why the particles fall more slowly

A statin makes your liver put more LDL receptors on its surface, and those receptors pull particles out of the blood. The NLA says treatment tends to clear the larger, more cholesterol-rich LDL particles first. The particles left behind carry less cholesterol each. Your LDL, which weighs the cholesterol, drops fast. Your ApoB, which counts the particles, drops more slowly.

Like towing the heaviest trucks first

Picture a jammed parking lot where the tow truck always takes the heaviest vehicles first. After an hour the total weight in the lot has dropped a lot, because the big rigs are gone. The number of vehicles has dropped less, because plenty of small cars are still there. LDL is the weight in the lot and ApoB is the vehicle count. The artery wall gets hit by vehicles.

What the leftover particles do

In a Copenhagen study of 13,015 people on statins, followed for about 8 years, those whose ApoB was above the group’s median while their LDL was below it had 1.49 times the heart attacks and 1.21 times the deaths of people with both below. A high LDL with a low ApoB wasn’t linked to more of either. The researchers concluded that in people on statins, ApoB “is a more accurate marker of all-cause mortality risk” than LDL.

The 2026 guideline’s recommendation follows from that. In adults on cholesterol medicine, above all with heart disease, diabetes, kidney and metabolic disease or high triglycerides, it says measuring ApoB “is reasonable to guide decisions regarding further therapeutic intensification once LDL-C and/or non–HDL-C goals are achieved”. For people with heart disease and severe high cholesterol, it adds an ApoB goal of under 55 once the LDL and non-HDL goals are met.

The best case for the myth

A skeptic would point out that the gap is an average, and people vary around it. Plenty of people on a statin reach both goals together. That’s true, and it’s why the guideline doesn’t ask everyone on a statin to test ApoB. It singles out people with diabetes, high triglycerides, an LDL brought under 70, or heart, kidney or metabolic disease, the groups where the two numbers are most likely to drift apart.

What to do

1. Keep taking your medicine. Never stop or change it on your own.
2. Once your LDL is at goal, ask for ApoB. It’s the same blood draw.
3. Bring both numbers to your prescriber. Ask what your ApoB goal is and whether anything should change. The guideline names ezetimibe, bempedoic acid, the PCSK9 antibodies and inclisiran as the nonstatin options an ApoB result can help decide on.